The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
4 pts

Opinion on  Pipex Pharmaceuticals Inc (PP)     Sector: Healthcare  >  Industry: Biotechnology & Drugs
Analyst says that it will double in a year.

Jul 20, 2007 04:03 PM GMT
111
Return Risk
+5.47% HIGH
Analyst

Analyst Recommendation  

Check out google finance and press on link to find more info. i think that this company will do very well and achieve exponential growth over the next year with it's new drugs that will help a lot of people.

Update 07/23:

pipex pharmaceuticals inc. is in the 3 phase for the development of one of their drugs and has many other drugs to come. These drugs will help a lot people if they work who are suffering from Alzeimer's disease, MS and many other horrible diseases that affect thousands of people.


PP:  This call was made on 07/20/07 @ $5.95
Rating:   Positive   $5.95 (07/20/07)
Closed:   08/14/2007 @ $6.1 (+2.52% in 25 days)
Target:   $11.00 (+84.87%) in > one year


+ Referring to this analysis:


Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment

Who voted on this idea?
Gain 38% 07/22/2007
investor 55% 07/22/2007


Ratings referring to this analysis Agree     Disagree



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +35.23% 368
2 Gerald Greene 18.14 +70.19% 206
3 stockmarketfunding.com 17.66 +25.78% 53
4 akiralegrand 13.47 +14.32% 61
5 anup2104 12.13 +69.23% 34


POPULAR STOCKS
Symbol Company Name Sentiment
AMZN Amazoncom Inc
JPM JPMorgan Chase & Co
GM General Motors Corp
RIMM Research in Motion Ltd
MO Altria Group Inc
EBAY eBay Inc

TODAY'S HEADLINES

TODAY'S TOP PICKS

 
Pipex Pharmaceuticals Inc (PP)
   SocialPicks Sentiment:    N/A

   This Quarter's Sentiment:
All:
100.0%
Top:
100.0%




Latest Picks by 111
Symbol SP Sentiment Rating Return Since
NCIT Positive +91.26% 07/30/07

View All >
   




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch